Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ACLY | P53396 | 1/20 | 0.42 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.35 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.35 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.35 |
| ▸ | DDIT3 | P35638 | 1/20 | 0.34 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.33 |
| ▸ | MGAT2 | Q10469 | 1/20 | 0.33 |
| ▸ | CCNE1 | P24864 | 5/20 | 0.32 |
| ▸ | CDK2 | P24941 | 5/20 | 0.32 |
| ▸ | CCND1 | P24385 | 4/20 | 0.32 |
| ▸ | CDK6 | Q00534 | 4/20 | 0.32 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.31 |
| ▸ | TP53 | P04637 | 1/20 | 0.31 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.31 |
| ▸ | HSD11B1 | P28845 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL28580229 | 0.82 | CNR1 (0.35) | ACLYCCNE1CDK2CCND1CDK6 | |
| SCHEMBL14971519 | 0.77 | MEN1 (0.44) | ALDH1A1 | |
| SCHEMBL1104697 | 0.77 | TP53 (0.46) | ACLYCYP2D6KCNH2HRH3TP53 | |
| SCHEMBL26470411 | 0.77 | CA1 (0.42) | ACLYCYP2D6KCNH2HRH3DDIT3 | |
| SCHEMBL12201520 | 0.75 | EPHX2 (0.39) | ACLYCYP2D6KCNH2HRH3DDIT3 | |
| SCHEMBL22959646 | 0.75 | CYP2D6 (0.37) | ACLYCYP2D6KCNH2HRH3DDIT3 | |
| SCHEMBL4478067 | 0.75 | KDM4E (0.42) | CYP2D6KCNH2HRH3TP53ALDH1A1 | |
| SCHEMBL12765367 | 0.75 | MAPK1 (0.40) | CCNE1CDK2CCND1CDK6TP53 | |
| SCHEMBL2424959 | 0.75 | CCNE1 (0.33) | CCNE1CDK2CCND1CDK6TP53 | |
| SCHEMBL12765346 | 0.75 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230135215-A1 | COMPOUNDS AS CDK2/4/6 INHIBITORS | FOCHON BIOSCIENCES, LTD. (CN) | 2023-05-04 | — | — | US | disclosed |
| US-20230135215-A1 | COMPOUNDS AS CDK2/4/6 INHIBITORS | FOCHON BIOSCIENCES, LTD. (CN) | 2023-05-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230135215-A1 | COMPOUNDS AS CDK2/4/6 INHIBITORS | CDK2, CDK6, CDK20 | ACLY 3600/4885CYP2D6 429/4885KCNH2 4809/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.